Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06ZVZ
|
|||
| Drug Name |
Duvelisib
|
|||
| Synonyms |
Duvelisib; 1201438-56-3; IPI-145; INK-1197; UNII-610V23S0JI; IPI 145; 610V23S0JI; INK-1147; Copiktra; IPI-145 (INK1197); Duvelisib [USAN:INN]; IPI145; INK1197; Copiktra (TN); AK145604; Duvelisib (IPI-145, INK1197); Duvel; Duvelisib
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Follicular lymphoma [ICD-11: 2A80; ICD-9: 202] | Approved | [1] | |
| Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2 | [2] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H17ClN6O
|
|||
| Canonical SMILES |
CC(C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
|
|||
| InChI |
1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1
|
|||
| InChIKey |
SJVQHLPISAIATJ-ZDUSSCGKSA-N
|
|||
| CAS Number |
CAS 1201438-56-3
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:131169
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN PI3-kinase delta (PIK3CD) | Target Info | Inhibitor | [2] |
| HUMAN PI3-kinase gamma (PIK3CG) | Target Info | Inhibitor | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 211155 | |||
| REF 2 | ClinicalTrials.gov (NCT04372602) Duvelisib to Combat COVID-19. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.